✦ LIBER ✦

A combination of 60 mg/m2 cisplatin (CDDP) and 200 mg/m2 carboplatin (CBDCA) is as active but less nephrotoxic than 120 mg/m2 CDDP in patients with advanced non-small cell lung cancer (NSCLC)

✍ Scribed by Giner, V.; Sculier, J.P.; Klastersky, J.; Bureau, G.; Thiriaux, J.; Efremidis, A.; Berchier, Mc.; Kroll, F.; Ries, F.; Mommen, P.; Paesmans, M.

Book ID: 122404931
Publisher: Elsevier Science
Year: 1993
Tongue: English
Weight: 188 KB
Volume: 8
Category: Article
ISSN: 0169-5002
DOI: 10.1016/0169-5002(93)90609-2

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

High (120 mg/m2) versus lower (60 mg/m2

High (120 mg/m2) versus lower (60 mg/m2 dose of cisplatin (CDDP) in combination with etoposide in the treatment of non small cell carcinoma (NSCLC)

📂 Article 📅 1986 🏛 Elsevier Science 🌐 English ⚖ 87 KB

6560 POSTER Prognostic factors affecting

6560 POSTER Prognostic factors affecting survival on pretreated patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) – Subgroup analysis in a randomized Ph II study of pemetrexed 500 mg/m2 and 1000 mg/m2

✍ Okabe, T.; Kubota, K.; Tamura, T.; Yamamoto, N.; Nakagawa, K.; Adachi, S.; Nambu 📂 Article 📅 2007 🏛 Elsevier Science 🌐 English ⚖ 62 KB

161 Carboplatin prescribed in mg/m2 in p

161 Carboplatin prescribed in mg/m2 in patients with advanced non small cell lung cancer (NSCLC): Is there an impact of the reached area under the curve (AUC) on response, survival and hematological toxicity?

✍ Paesmans, M.; Sculier, J.P.; Thiriaux, J.; Bureau, G.; Giner, V.; Efremidis, A.; 📂 Article 📅 1997 🏛 Elsevier Science 🌐 English ⚖ 319 KB